143 related articles for article (PubMed ID: 30058145)
1. Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia.
Rosenthal J; Naqvi AS; Luo M; Wertheim G; Paessler M; Thomas-Tikhonenko A; Rheingold SR; Pillai V
Am J Hematol; 2018 Nov; 93(11):E352-E355. PubMed ID: 30058145
[No Abstract] [Full Text] [Related]
2. B-acute leukemic lymphoblasts versus hematogones: the wolf in sheep's clothing/.
Kalff A; Juneja S
Leuk Lymphoma; 2009 Apr; 50(4):523-4. PubMed ID: 19373647
[No Abstract] [Full Text] [Related]
3. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
Fry TJ; Shah NN; Orentas RJ; Stetler-Stevenson M; Yuan CM; Ramakrishna S; Wolters P; Martin S; Delbrook C; Yates B; Shalabi H; Fountaine TJ; Shern JF; Majzner RG; Stroncek DF; Sabatino M; Feng Y; Dimitrov DS; Zhang L; Nguyen S; Qin H; Dropulic B; Lee DW; Mackall CL
Nat Med; 2018 Jan; 24(1):20-28. PubMed ID: 29155426
[TBL] [Abstract][Full Text] [Related]
4. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases.
Raponi S; De Propris MS; Intoppa S; Milani ML; Vitale A; Elia L; Perbellini O; Pizzolo G; Foá R; Guarini A
Leuk Lymphoma; 2011 Jun; 52(6):1098-107. PubMed ID: 21348573
[TBL] [Abstract][Full Text] [Related]
5. T-cell adoptive immunotherapy for acute lymphoblastic leukemia.
Fry TJ; Mackall CL
Hematology Am Soc Hematol Educ Program; 2013; 2013():348-53. PubMed ID: 24319203
[TBL] [Abstract][Full Text] [Related]
6. [Characteristics of 4 specific target antigens in adult acute lymphoblastic leukemia].
Lin ZK; Zhang R; Ge Z; Liu J; Wu YJ; Guo X; Qiao C; Qiu HR; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):289-95. PubMed ID: 23628018
[TBL] [Abstract][Full Text] [Related]
7. Screening of Variations in CD22 Gene in Children with B-Precursor Acute Lymphoblastic Leukemia.
Aslar Oner D; Akin DF; Sipahi K; Mumcuoglu M; Ezer U; Kürekci AE; Akar N
Genet Test Mol Biomarkers; 2016 Sep; 20(9):552-5. PubMed ID: 27486888
[TBL] [Abstract][Full Text] [Related]
8. A novel full-human CD22-CAR T cell therapy with potent activity against CD22
Tan Y; Cai H; Li C; Deng B; Song W; Ling Z; Hu G; Yang Y; Niu P; Meng G; Cheng W; Xu J; Duan J; Wang Z; Yu X; Feng X; Zhou J; Pan J
Blood Cancer J; 2021 Apr; 11(4):71. PubMed ID: 33839735
[No Abstract] [Full Text] [Related]
9. Dual CD19/CD22 CAR T Cells Show Feasibility in Pediatric/Young Adult B-ALL.
Cancer Discov; 2021 Dec; 11(12):2958. PubMed ID: 34686527
[TBL] [Abstract][Full Text] [Related]
10. Characterization of CD22 expression in acute lymphoblastic leukemia.
Shah NN; Stevenson MS; Yuan CM; Richards K; Delbrook C; Kreitman RJ; Pastan I; Wayne AS
Pediatr Blood Cancer; 2015 Jun; 62(6):964-9. PubMed ID: 25728039
[TBL] [Abstract][Full Text] [Related]
11. Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B-acute lymphoblastic leukaemia.
Ryland GL; Barraclough A; Fong CY; Fleming S; Bajel A; Hofmann O; Westerman D; Grimmond S; Blombery P
Br J Haematol; 2020 Oct; 191(1):123-126. PubMed ID: 32648276
[No Abstract] [Full Text] [Related]
12. Anti-CD19 and anti-CD22 monoclonal antibodies increase the effectiveness of chemotherapy in Pre-B acute lymphoblastic leukemia cell lines.
Stanciu-Herrera C; Morgan C; Herrera L
Leuk Res; 2008 Apr; 32(4):625-32. PubMed ID: 17706771
[TBL] [Abstract][Full Text] [Related]
13. A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia.
Wang Y; Yang Y; Hong R; Zhao H; Wei G; Wu W; Xu H; Cui J; Zhang Y; Chang AH; Hu Y; Huang H
Blood Cancer J; 2020 Oct; 10(10):105. PubMed ID: 33077713
[No Abstract] [Full Text] [Related]
14. CD19 negative and dim precursor B-lineage acute lymphoblastic leukemias: real-world challenges in a targeted-immunotherapy era.
Bommannan BKK; Arumugam JR; Sundersingh S; Rajan PT; Radhakrishnan V; Sagar TG
Leuk Lymphoma; 2019 Dec; 60(13):3154-3160. PubMed ID: 31184238
[TBL] [Abstract][Full Text] [Related]
15. Labile CD22 and CD19 expression in a case of Philadelphia chromosome-like acute lymphoblastic leukemia.
Mukae J; Sadato D; Toya T; Watanabe S; Hirama C; Konuma R; Shimizu H; Najima Y; Kobayashi T; Kato M; Ohki K; Oboki K; Harada H; Ohashi K; Deguchi T; Harada Y; Doki N
Leuk Lymphoma; 2022 Dec; 63(13):3261-3264. PubMed ID: 36102781
[No Abstract] [Full Text] [Related]
16. CD22ΔE12 as a molecular target for corrective repair using RNA trans-splicing: anti-leukemic activity of a rationally designed RNA trans-splicing molecule.
Uckun FM; Qazi S; Ma H; Reaman GH; Mitchell LG
Integr Biol (Camb); 2015 Feb; 7(2):237-49. PubMed ID: 25567759
[TBL] [Abstract][Full Text] [Related]
17. Altered CD19/CD22 balance in Egyptian children and adolescents with systemic lupus erythematosus.
El-Sayed ZA; Ragab SM; Khalifa KA; El Ashmawy RA
Egypt J Immunol; 2009; 16(1):27-38. PubMed ID: 20726320
[TBL] [Abstract][Full Text] [Related]
18. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection.
Ciudad J; Orfao A; Vidriales B; Macedo A; Martínez A; González M; López-Berges MC; Valverde B; San Miguel JF
Haematologica; 1998 Dec; 83(12):1069-75. PubMed ID: 9949623
[TBL] [Abstract][Full Text] [Related]
19. CD19-negative B-lineage acute lymphoblastic leukemia: A diagnostic and therapeutic challenge.
Bansal S; Sharma U; Jain A; Sharma R; Yagnik B
Indian J Pathol Microbiol; 2017; 60(4):596-598. PubMed ID: 29323085
[TBL] [Abstract][Full Text] [Related]
20. CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment.
Mejstríková E; Hrusak O; Borowitz MJ; Whitlock JA; Brethon B; Trippett TM; Zugmaier G; Gore L; von Stackelberg A; Locatelli F
Blood Cancer J; 2017 Dec; 7(12):659. PubMed ID: 29259173
[No Abstract] [Full Text] [Related]
[Next] [New Search]
